Ben Valery Sionov, Matvey Tsivian, Pavel Bakaleyschik, Ami Abraham Sidi, Alexander Tsivian
{"title":"经尿道同时切除高级别膀胱尿路上皮癌和良性前列腺增生的肿瘤安全性。","authors":"Ben Valery Sionov, Matvey Tsivian, Pavel Bakaleyschik, Ami Abraham Sidi, Alexander Tsivian","doi":"10.1080/2090598X.2022.2142365","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To examine the oncological safety of simultaneous resection of bladder tumor and prostate in the presence of non-muscle invasive high-grade urothelial carcinoma of the bladder (UCB).</p><p><strong>Materials and methods: </strong>Between 2007 and 2019, 170 men with high-grade UCB who had a follow-up of at least 12 months were included in the study, including 123 with transurethral resection of bladder tumor (TURBT) only and 47 with simultaneous TURBT and transurethral resection of the prostate (TURP). We recorded and compared patients' clinicopathological parameters, recurrence, and progression rates during the follow-up period, as well as time to UCB recurrence in the bladder and the prostatic urethra/fossa.</p><p><strong>Results: </strong>Baseline demographic and pathological characteristics were comparable between the groups. At a median follow-up of 31 months in both groups, there were no significant differences in recurrence rates in the bladder and the prostatic urethra/fossa in either group (34.1% and 7.3% vs. 36.2 and 6.4%, p=0.402, p=0.363). No statistically significant differences were found between the two groups in terms of follow-up time, elapsed time to recurrence, or and progression in the bladder or prostatic urethra/fossa.</p><p><strong>Conclusions: </strong>Simultaneous TURBT and TURP in the presence of high-grade UCB appears to be oncologically safe in selected patients.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208128/pdf/","citationCount":"0","resultStr":"{\"title\":\"Oncological safety of simultaneous transurethral resection of high-grade urothelial carcinoma of the bladder and benign prostatic hyperplasia.\",\"authors\":\"Ben Valery Sionov, Matvey Tsivian, Pavel Bakaleyschik, Ami Abraham Sidi, Alexander Tsivian\",\"doi\":\"10.1080/2090598X.2022.2142365\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To examine the oncological safety of simultaneous resection of bladder tumor and prostate in the presence of non-muscle invasive high-grade urothelial carcinoma of the bladder (UCB).</p><p><strong>Materials and methods: </strong>Between 2007 and 2019, 170 men with high-grade UCB who had a follow-up of at least 12 months were included in the study, including 123 with transurethral resection of bladder tumor (TURBT) only and 47 with simultaneous TURBT and transurethral resection of the prostate (TURP). We recorded and compared patients' clinicopathological parameters, recurrence, and progression rates during the follow-up period, as well as time to UCB recurrence in the bladder and the prostatic urethra/fossa.</p><p><strong>Results: </strong>Baseline demographic and pathological characteristics were comparable between the groups. At a median follow-up of 31 months in both groups, there were no significant differences in recurrence rates in the bladder and the prostatic urethra/fossa in either group (34.1% and 7.3% vs. 36.2 and 6.4%, p=0.402, p=0.363). No statistically significant differences were found between the two groups in terms of follow-up time, elapsed time to recurrence, or and progression in the bladder or prostatic urethra/fossa.</p><p><strong>Conclusions: </strong>Simultaneous TURBT and TURP in the presence of high-grade UCB appears to be oncologically safe in selected patients.</p>\",\"PeriodicalId\":8113,\"journal\":{\"name\":\"Arab Journal of Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208128/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arab Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/2090598X.2022.2142365\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arab Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/2090598X.2022.2142365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨非肌肉浸润性高级别膀胱尿路上皮癌(UCB)同时行膀胱肿瘤和前列腺切除术的肿瘤学安全性。材料和方法:在2007年至2019年期间，170名随访至少12个月的高级别UCB男性被纳入研究，其中123名仅行经尿道膀胱肿瘤切除术(TURBT)， 47名同时行TURBT和经尿道前列腺切除术(TURP)。我们记录并比较患者在随访期间的临床病理参数、复发率和进展率，以及膀胱和前列腺尿道/窝UCB复发的时间。结果:两组间的基线人口学和病理特征具有可比性。在中位随访31个月时，两组患者膀胱和前列腺尿道/窝复发率无显著差异(34.1%和7.3% vs. 36.2%和6.4%，p=0.402, p=0.363)。两组在随访时间、复发时间、膀胱或前列腺尿道/窝进展方面无统计学差异。结论:在选定的患者中，在存在高级别UCB的情况下同时进行turt和TURP似乎是肿瘤安全的。
Oncological safety of simultaneous transurethral resection of high-grade urothelial carcinoma of the bladder and benign prostatic hyperplasia.
Objectives: To examine the oncological safety of simultaneous resection of bladder tumor and prostate in the presence of non-muscle invasive high-grade urothelial carcinoma of the bladder (UCB).
Materials and methods: Between 2007 and 2019, 170 men with high-grade UCB who had a follow-up of at least 12 months were included in the study, including 123 with transurethral resection of bladder tumor (TURBT) only and 47 with simultaneous TURBT and transurethral resection of the prostate (TURP). We recorded and compared patients' clinicopathological parameters, recurrence, and progression rates during the follow-up period, as well as time to UCB recurrence in the bladder and the prostatic urethra/fossa.
Results: Baseline demographic and pathological characteristics were comparable between the groups. At a median follow-up of 31 months in both groups, there were no significant differences in recurrence rates in the bladder and the prostatic urethra/fossa in either group (34.1% and 7.3% vs. 36.2 and 6.4%, p=0.402, p=0.363). No statistically significant differences were found between the two groups in terms of follow-up time, elapsed time to recurrence, or and progression in the bladder or prostatic urethra/fossa.
Conclusions: Simultaneous TURBT and TURP in the presence of high-grade UCB appears to be oncologically safe in selected patients.
期刊介绍：
The Arab Journal of Urology is a peer-reviewed journal that strives to provide a high standard of research and clinical material to the widest possible urological community worldwide. The journal encompasses all aspects of urology including: urological oncology, urological reconstructive surgery, urodynamics, female urology, pediatric urology, endourology, transplantation, erectile dysfunction, and urinary infections and inflammations. The journal provides reviews, original articles, editorials, surgical techniques, cases reports and correspondence. Urologists, oncologists, pathologists, radiologists and scientists are invited to submit their contributions to make the Arab Journal of Urology a viable international forum for the practical, timely and state-of-the-art clinical urology and basic urological research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
